Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

NCT02406092 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Vincristine
DRUG: Prednisone
DRUG: Fludarabine

Sponsor

Hoffmann-La Roche